T LYMPHOCYTE, T CELL RECEPTOR, CELLULAR IMMUNITY, IMMUNOTHERAPY

T 淋巴细胞、T 细胞受体、细胞免疫、免疫治疗

• 批准号: 7715767
• 负责人: MARY S LANIER
• 金额: $ 3.56万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7715767
• 关键词: Acute; Adoptive Transfer; Affect; Antigens; Cell Survival; Cells; Cellular Immunity; Chronic; Chronic Disease; Computer Retrieval of Information on Scientific Projects Database; Development; Exposure to; Funding; Grant; Immune; Immune response; Immunotherapy; Infection; Institution; Kinetics; Lead; Lewis Lung Carcinoma; Lymphocyte; Lymphocytic choriomeningitis virus; Modeling; Neoplasm Transplantation; Population; Receptor Cell; Research; Research Personnel; Resources; Source; T-Lymphocyte; Therapeutic; Time; Transgenic Model; United States National Institutes of Health; Work; cytokine; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examines how ongoing acute and chronic infections and exposure to tumors affect naive bystander T cell populations. Out studies analyze the status, kinetics, and stability of naive T cells during acute and chronic infections and to determine how chronic antigen exposure during persistent infections or persisting tumors has on the ability of bystander naive T cells to mount immune responses. In addition, to determine the effect of introducing therapeutic cytokines during a chronic infection or tumor model has on bystander naive T cells. Using a TCR transgenic model we will expose, by adoptive transfer, OVA TCR naive T cells to acute LCMV, chronic LCMV infection or Lewis Lung Carcinoma tumor transplant model. Recovered OVA naive cells will then be adoptively transferred into normal LCMV immune recipients to determine their ability to respond to OVA infection. We are working to develop clues in the timing of therapies that will lead to therapeutic developments for targeting naive T cell viability during chronic diseases and immune suppression.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究探讨了正在进行的急性和慢性感染以及暴露于肿瘤如何影响幼稚旁观者T细胞群。我们的研究分析了急性和慢性感染期间幼稚T细胞的状态，动力学和稳定性，并确定持续感染或持续肿瘤期间慢性抗原暴露如何影响旁观者幼稚T细胞产生免疫应答的能力。此外，为了确定在慢性感染或肿瘤模型期间引入治疗性细胞因子对旁观者幼稚T细胞的影响。使用TCR转基因模型，我们将通过过继转移将OVA TCR初始T细胞暴露于急性LCMV、慢性LCMV感染或刘易斯肺癌肿瘤移植模型。然后，将经传代的OVA幼稚细胞过继转移到正常的LCMV免疫受体中，以确定它们对OVA感染的应答能力。我们正在努力开发治疗时机的线索，这将导致针对慢性疾病和免疫抑制期间幼稚T细胞活力的治疗发展。